Heat-Shock Protein 90 Controls the Expression of Cell-Cycle Genes by Stabilizing Metazoan-Specific Host-Cell Factor HCFC1.


Journal

Cell reports
ISSN: 2211-1247
Titre abrégé: Cell Rep
Pays: United States
ID NLM: 101573691

Informations de publication

Date de publication:
05 11 2019
Historique:
received: 19 03 2019
revised: 06 08 2019
accepted: 27 09 2019
entrez: 7 11 2019
pubmed: 7 11 2019
medline: 25 9 2020
Statut: ppublish

Résumé

Molecular chaperones such as heat-shock proteins (HSPs) help in protein folding. Their function in the cytosol has been well studied. Notably, chaperones are also present in the nucleus, a compartment where proteins enter after completing de novo folding in the cytosol, and this raises an important question about chaperone function in the nucleus. We performed a systematic analysis of the nuclear pool of heat-shock protein 90. Three orthogonal and independent analyses led us to the core functional interactome of HSP90. Computational and biochemical analyses identify host cell factor C1 (HCFC1) as a transcriptional regulator that depends on HSP90 for its stability. HSP90 was required to maintain the expression of HCFC1-targeted cell-cycle genes. The regulatory nexus between HSP90 and the HCFC1 module identified in this study sheds light on the relevance of chaperones in the transcription of cell-cycle genes. Our study also suggests a therapeutic avenue of combining chaperone and transcription inhibitors for cancer treatment.

Identifiants

pubmed: 31693902
pii: S2211-1247(19)31288-4
doi: 10.1016/j.celrep.2019.09.084
pii:
doi:

Substances chimiques

Chromatin 0
HSP90 Heat-Shock Proteins 0
Host Cell Factor C1 0
CDK9 protein, human EC 2.7.11.22
Cyclin-Dependent Kinase 9 EC 2.7.11.22

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1645-1659.e9

Subventions

Organisme : Medical Research Council
ID : MC_UU_00025/8
Pays : United Kingdom

Informations de copyright

Copyright © 2019 The Author(s). Published by Elsevier Inc. All rights reserved.

Auteurs

Aneliya Antonova (A)

Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany; Faculty of Biology, University of Freiburg, Freiburg, Germany.

Barbara Hummel (B)

Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany.

Ashkan Khavaran (A)

Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany; Faculty of Medicine, University of Freiburg, Freiburg, Germany.

Desiree M Redhaber (DM)

German Consortium for Translational Cancer Research (DKTK), Partner Site Freiburg and German Cancer Research Center (DKFZ), Heidelberg, Germany; Department of Hematology, Oncology and Stem Cell Transplantation, Faculty of Medicine, Medical Center - University of Freiburg, Freiburg, Germany; Faculty of Biology, University of Freiburg, Freiburg, Germany.

Fernando Aprile-Garcia (F)

Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany.

Prashant Rawat (P)

Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany; Faculty of Biology, University of Freiburg, Freiburg, Germany.

Kathrin Gundel (K)

Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany.

Megan Schneck (M)

Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany.

Erik C Hansen (EC)

Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany.

Jan Mitschke (J)

Department of Hematology, Oncology and Stem Cell Transplantation, Faculty of Medicine, Medical Center - University of Freiburg, Freiburg, Germany.

Gerhard Mittler (G)

Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany.

Cornelius Miething (C)

German Consortium for Translational Cancer Research (DKTK), Partner Site Freiburg and German Cancer Research Center (DKFZ), Heidelberg, Germany; Department of Hematology, Oncology and Stem Cell Transplantation, Faculty of Medicine, Medical Center - University of Freiburg, Freiburg, Germany; BIOSS Centre for Biological Signalling Studies, University of Freiburg, Freiburg, Germany.

Ritwick Sawarkar (R)

Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany; CIBSS Centre for Integrative Biological Signalling Studies, University of Freiburg, Freiburg, Germany; MRC Toxicology Unit, University of Cambridge, Cambridge, UK. Electronic address: rs2099@cam.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH